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Abstract
Defensins and surfactant protein A (SP-A) and SP-D are antimicrobial components of the pulmonary innate
immune system. The purpose of this study was to determine the extent to which parainfluenza type 3 virus
infection in neonatal lambs alters expression of sheep beta-defensin 1 (SBD-1), SP-A, and SP-D, all of which
are constitutively transcribed by respiratory epithelia. Parainfluenza type 3 viral antigen was detected by
immunohistochemistry (IHC) in the bronchioles of all infected lambs 3 days postinoculation and at
diminished levels 6 days postinoculation, but it was absent 17 days postinoculation. At all times
postinoculation, lung homogenates from parainfluenza type 3 virus-inoculated animals had increased SBD-1,
SP-A, and SP-D mRNA levels as detected by fluorogenic real-time reverse transcriptase PCR. Protein levels of
SP-A in lung homogenates detected by quantitative-competitive enzyme-linked immunosorbent assay and
protein antigen of SP-A detected by IHC were not altered. These studies demonstrate that parainfluenza type
3 virus infection results in enhanced expression of constitutively transcribed innate immune factors expressed
by respiratory epithelia and that this increased expression occurs concurrently with decreased viral
replication.
Disciplines
Large or Food Animal and Equine Medicine | Veterinary Pathology and Pathobiology
Comments
This article is from Clinical and Diagnostic Laboratory Immunology 11, no. 3 (May 2004): 599–607,
doi:10.1128/CDLI.11.3.599–607.2004.
Authors
Branka Grubor, Jack M. Gallup, David K. Meyerholz, Erika C. Crouch, Richard B. Evans, Kim A. Brogden,
Howard D. Lehmkuhl, and Mark R. Ackermann
This article is available at Iowa State University Digital Repository: http://lib.dr.iastate.edu/vpath_pubs/6
  
10.1128/CDLI.11.3.599-607.2004. 
2004, 11(3):599. DOI:Clin. Diagn. Lab. Immunol. 
Lehmkuhl and Mark R. Ackermann
C. Crouch, Richard B. Evans, Kim A. Brogden, Howard D. 
Branka Grubor, Jack M. Gallup, David K. Meyerholz, Erika
 
Type 3 Pneumonia in Neonatal Lambs
Replication during Parainfluenza Virus
mRNA Levels and Reduced Viral 
Enhanced Surfactant Protein and Defensin
http://cvi.asm.org/content/11/3/599
Updated information and services can be found at: 
These include:
REFERENCES
http://cvi.asm.org/content/11/3/599#ref-list-1at: 
This article cites 50 articles, 16 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 February 25, 2013 by IO
W
A STATE UNIVERSITY
http://cvi.asm
.org/
D
ow
nloaded from
 
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, May 2004, p. 599–607 Vol. 11, No. 3
1071-412X/04/$08.000 DOI: 10.1128/CDLI.11.3.599–607.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Enhanced Surfactant Protein and Defensin mRNA Levels and
Reduced Viral Replication during Parainfluenza Virus
Type 3 Pneumonia in Neonatal Lambs
Branka Grubor,1* Jack M. Gallup,1 David K. Meyerholz,1 Erika C. Crouch,2
Richard B. Evans,3 Kim A. Brogden,4 Howard D. Lehmkuhl,4
and Mark R. Ackermann1
Department of Veterinary Pathology1 and Department of Veterinary Diagnostic and Production Animal Medicine,3 College of
Veterinary Medicine, Iowa State University, Ames, Iowa 50011-1250, Department of Pathology, University of
Washington, St. Louis, Missouri,2 and Respiratory Diseases of Ruminants Research Unit, Agricultural
Research Service, U.S. Department of Agriculture-National Animal Disease Center, Ames,
Iowa 500104
Received 21 October 2003/Returned for modification 26 November 2003/Accepted 2 January 2004
Defensins and surfactant protein A (SP-A) and SP-D are antimicrobial components of the pulmonary innate
immune system. The purpose of this study was to determine the extent to which parainfluenza type 3 virus
infection in neonatal lambs alters expression of sheep beta-defensin 1 (SBD-1), SP-A, and SP-D, all of which
are constitutively transcribed by respiratory epithelia. Parainfluenza type 3 viral antigen was detected by
immunohistochemistry (IHC) in the bronchioles of all infected lambs 3 days postinoculation and at diminished
levels 6 days postinoculation, but it was absent 17 days postinoculation. At all times postinoculation, lung
homogenates from parainfluenza type 3 virus-inoculated animals had increased SBD-1, SP-A, and SP-D mRNA
levels as detected by fluorogenic real-time reverse transcriptase PCR. Protein levels of SP-A in lung homog-
enates detected by quantitative-competitive enzyme-linked immunosorbent assay and protein antigen of SP-A
detected by IHC were not altered. These studies demonstrate that parainfluenza type 3 virus infection results
in enhanced expression of constitutively transcribed innate immune factors expressed by respiratory epithelia
and that this increased expression occurs concurrently with decreased viral replication.
Paramyxovirus infections by respiratory syncytial virus
(RSV) and parainfluenza type 1 (PI-1), PI-2, PI-3, and PI-4
viruses are major causes of respiratory disease in young chil-
dren. Although RSV is the cause of 50 to 90% of hospitaliza-
tions for bronchiolitis, PI-3 virus causes a spectrum of diseases
similar to RSV diseases (23). These include respiratory tract
infections that are complicated in 30 to 50% of cases by otitis
media. Most children are infected with PI-3 virus by 2 years of
age and with PI-1 and PI-2 viruses by 5 years of age (33, 44).
Ovine PI-3 virus infection is a spontaneous disease of sheep
that can cause respiratory infections in growing lambs (7 days
of age) experimentally that are similar to those seen in children
(36). Immunity to RSV and PI-3 virus are often not long lasting
or protective, and traditional therapies (bronchodilators, ste-
roids, and ribavirin) for severe paramyxovirus infections gen-
erally have no overall significant benefit (28, 47). In contrast,
innate immune factors, such as defensins and surfactant pro-
teins, are increasingly appreciated for their direct and indirect
activities against viral infections.
Defensins are cationic peptides produced by a wide range of
species (8) that have activities against bacterial, viral, and fun-
gal pathogens (8, 17, 24). Human beta-defensin 1 (HBD-1) and
HBD-2 are thought to exert their antimicrobial activities by
forming pores and causing membrane disruption (37). Other
activities include healing of epithelium; monocytic, dendritic
and T-cell chemotaxis (50); synergism with other antimicrobial
factors, such as lysozyme and lactoferrin (46); and complement
activation (46). HBD-1 also participates in cell regulation by
promotion of cell differentiation and maturation in vitro (19)
and inactivates enveloped viruses (20, 46). In addition, alpha-
defensins have been shown to induce protection against human
immunodeficiency virus type 1 (HIV-1) (52). Sheep beta-de-
fensin 1 (SBD-1) is a member of the beta-defensin family with
constitutive expression and tissue distribution similar to those
of HBD-1 (29, 30). SBD-1 expression is developmentally reg-
ulated in late gestation through the neonatal period, with max-
imal expression in some tissues reached weeks after birth (29).
This suggests a window of immature SBD-1 expression in the
neonate that provides an environment conducive to more se-
vere PI-3 virus infection.
Surfactant protein A (SP-A) and SP-D are calcium-depen-
dent lectins and members of the collectin family (12, 13, 40). In
the lung, SP-A and SP-D are secreted by type II pneumocytes
and Clara cells and have important roles in immunomodula-
tion, surfactant homeostasis, and pulmonary defense (12, 13,
14, 39, 40, 43). SP-A and SP-D interact with bacterial, fungal,
and viral pathogens by binding and, in some cases, forming
aggregates (12, 13, 27, 40, 43, 45), which can inactivate the
pathogen, stimulate phagocytosis, enhance antigen presenta-
tion, potentiate oxidant responses of neutrophils (12, 13, 14,
27, 32, 39, 43, 51), and activate macrophages via Toll-like
* Corresponding author. Mailing address: Department of Veteri-
nary Pathology, 2740 Veterinary Medicine, Iowa State University,
Ames, IA 50011-1250. Phone: (515) 294-3647. Fax: (515) 294-5423.
E-mail: brankag@iastate.edu.
599
 o
n
 February 25, 2013 by IO
W
A STATE UNIVERSITY
http://cvi.asm
.org/
D
ow
nloaded from
 
receptor 4 (21). Deficiency of SP-A and SP-D in vivo is asso-
ciated with increased risk of infection (3) and may contribute
to enhanced inflammation and inflammatory-cell recruitment
during infection (39).
The susceptibility of neonatal lambs (5 days of age) to PI-3
virus and the effect of PI-3 virus infection on the expression of
beta-defensins and surfactant proteins have not been deter-
mined. Potential decreases in expression may leave the lung
predisposed to viral reinfection or secondary bacterial infec-
tion. The purpose of this study was to test the hypothesis that
PI-3 virus infection alters the expression of the constitutively
transcribed innate immune factors SBD-1, SP-A, and SP-D in
the lungs of neonatal lambs.
MATERIALS AND METHODS
Experimental design. Eighteen colostrum-fed neonatal lambs (3 to 5 days old),
of both sexes and mixed breed, were obtained from Laboratory Animal Re-
sources, Iowa State University. The lambs were randomly assigned to two groups,
and each group was maintained in a separate climate-controlled isolation room
until sacrifice. After a 24-h period of acclimation, one group (n  9 animals)
received saline while the other (n 9 animals) received the ovine PI-3 virus. The
viral inoculum consisted of infectious supernatant prepared from a culture of
ovine fetal turbinate (OFTu) cells previously infected with ovine PI-3 virus strain
DH-1, according to a standard procedure (35). The animals received 10 ml
intratracheally and 2 ml intranasally of either viral inoculum containing 106.9
50% tissue culture infective doses of PI-3 virus per ml or pyrogen-free saline.
Clinical signs and temperatures were observed and logged daily. Three animals
from each group were euthanized on day 3, 6, or 17 postinoculation (p.i.) using
1 ml of euthanasia solution (Beuthanasia-D Special [pentobarbital sodium];
Schering-Plough Animal Health) per 10 kg of body weight injected into the
external jugular vein. This protocol was approved by the Iowa State University
Animal Care Review Committee.
Collection of samples. Lungs were evaluated for gross lesions, and tissue
samples (with the most severe gross lesions from infected animals) from all lung
lobes were collected into cryovials, snap-frozen in liquid nitrogen, and stored at
80°C until analysis, when a vial from each animal was used for RNA isolation
by TRIZOL extraction, cDNA production, and subsequent real-time reverse
transcriptase (RT) PCR analysis. The remaining lung tissue was fixed in 10%
buffered formalin for histopathological evaluation of PI-3 virus-induced lesions
and for immunohistochemical (IHC) staining of PI-3 viral antigen and SP-A. The
sections used for histopathological evaluation were stained with hematoxylin and
eosin.
Serum analysis. Five to 10 ml of whole blood was collected from each animal,
once before the inoculation of pyrogen-free saline or PI-3 virus inoculum and
once before euthanasia. A microtiter plate-based serum virus neutralization test
was used to quantitate ovine PI-3 virus neutralizing antibodies as described
previously (34).
IHC detection of PI-3 viral antigen. Sections of lung on silanated glass slides
were stained with antibody to PI-3 virus antigen using a biotin-streptavidin-
peroxidase method developed in our laboratory (48). Briefly, the slides were
heated in an oven at 58°C for 30 min and deparaffinized using xylene and a series
of graded alcohols until they were fully hydrated in ultrapure water. Next, a
protease mixture, Protease XIV (Sigma, St. Louis, Mo.) was used for antigen
retrieval in the following way. Section-containing slides were warmed to 37°C for
15 min in 50 mM Tris buffer, pH 7.6 (prewarmed to 37°C), and then placed into
0.1% Protease XIV solution (prewarmed to 37°C) for 12 min at room temper-
ature. The slides were subsequently rinsed with 50 mM Tris, pH 7.6, twice for 5
min each time, rinsed once with BioGenex (San Ramon, Calif.) phosphate-
buffered saline (BPBS) (standard PBS containing 0.1% Tween 20, pH 7.4–20
OptiMax wash buffer), and washed in BPBS for 5 min. The glass regions on each
slide above and below the tissue-containing areas were wiped off and lined with
a fast-drying liquid wax pen (PAP-Pen; BioGenex), creating hydrophobic bound-
aries to protect against reagent loss. The slides were then rinsed in BPBS for 5
min. In order to minimize nonspecific background staining, the slides were
incubated for 20 min in 20% normal swine serum (NSS) (Invitrogen, Grand
Island, N.Y.) diluted in BPBS. Without being rinsed, all of the slides were then
placed in polypropylene five-slide mailers (5-Slide Plastic Mailer Containers;
Evergreen Scientific, Los Angeles, Calif.), each containing 18 ml of either pri-
mary goat polyclonal anti-bovine PI-3 primary antibody (catalog no. 210-70-PI3;
VMRD, Pullman, Wash.) diluted 1:1,000 with 5% NSS in BioGenex diluent
(common reagent diluent) or colostrum-deprived non-pathogen-exposed fetal
normal goat serum (fetal goat serum sample accession no. 966; obtained from
H. D. Lehmkuhl, National Animal Disease Center, Ames, Iowa) for control
slides, and incubated for 48 h in a cold room at 4°C. The slides were then warmed
to room temperature for 30 min, rinsed with BPBS, treated with 3% hydrogen
peroxide solution for 40 min (to quench endogenous tissue peroxidase activity),
and rinsed again with BPBS for 5 min. The sections were preincubated with a
biotinylated rabbit anti-goat secondary antibody (catalog no. 16-13-06; biotinyl-
ated rabbit anti-goat immunoglobulin G [IgG] [heavy and light chains]; Kirkeg-
aard & Perry Laboratories, Gaithersburg, Md.) diluted 1:400 in BioGenex di-
luent containing 5% normal sheep serum (Sigma) for 30 s. The slides were then
tilted to remove this solution from them, and without an intervening buffer rinse,
incubated again with the same reagent for 45 min. The slides were then rinsed
with BPBS and allowed to stand in BPBS for 5 min. Supersensitive streptavidin-
conjugated peroxidase (BioGenex) was applied for 45 min, followed by thorough
rinsing with BPBS, a 5-min incubation in BPBS, and a 4-min incubation with the
peroxidase-sensitive chromogen Nova Red (Vector, Burlingame, Calif.). The
slides were rinsed thoroughly with ultrapure water, counterstained for 2 min with
one-quarter-strength acidified (pH 5.2) hematoxylin (Shandon Lipshaw/Lerner),
rinsed three times with ultrapure water, immersed in Scott’s tap water (an pH
8.0 tap water-like bluing agent for hematoxylin made by adding 83 mM magne-
sium sulfate and 24 mM sodium bicarbonate to ultrapure water) for 1 min, rinsed
briefly in ultrapure water, and dehydrated through a series of graded alcohol and
xylene baths. The slides were finally coverslipped using 3 drops of mounting
medium (Permount; Fisher Scientific, Hanover, Ill.) in conjunction with either
24- by 40- or 24- by 50-mm glass coverslips (Richard Allen Scientific, Kalamazoo,
Mich.). A reddish color (the oxidized, peroxidase-developed Nova Red chromo-
gen precipitate) observed by light microscopy within the tissue sections on sam-
ple slides was interpreted as a positive IHC reaction. Control sections incubated
with fetal normal goat serum instead of primary polyclonal goat anti-PI-3 anti-
body were found to lack IHC staining. Lung sections from all 18 animals were
evaluated.
IHC detection of SP-A protein. Sections of lung on silanated glass slides were
first heated in an oven at 58°C for 30 min and deparaffinized and rehydrated
using the same solvent series described above. Antigen retrieval was achieved
using a power-adjustable commercial microwave oven (Panasonic, Danville, Ky.)
and Citra Plus pH 6.2 antigen retrieval solution (Citra Plus buffer 10 concen-
trate; BioGenex) by putting the slides in plastic (eight-slide) Coplin containers
with the Citra Plus pH 6.2 solution (already diluted 1:10 with ultrapure water to
achieve the 1 working solution). The retrieval solutions containing the slides
were brought just to boiling in the microwave oven at an initial power setting of
1,000 W, the microwave oven was stopped, and then the slides in Citra Plus were
heated in the microwave oven for an additional 10 min at a reduced power setting
of 300 W. Following antigen retrieval, the containers with slides were placed at
20°C for 20 min to speed cooling back to room temperature, after which the
slides were rinsed twice with water and bathed in BPBS for 5 min. Using a
fast-drying liquid wax pen (PAP-pen), reagent barrier lines were applied to each
slide at this point (as described above for PI-3 IHC). Next, the slides were
incubated for 20 min in a blocking solution of 1% bovine serum albumin (BSA)
(IgG-free, protease-free BSA; Jackson Immunoresearch Laboratories Inc.) in
BPBS. The sections were then placed on metal slide racks in a humidified, sealed
container and incubated with anti-SP-A primary antibody or control IgG- or
IgM-containing serum for 3 days in a cold room at 4°C. The primary antibody was
mouse IgM anti-human SP-A (catalog no. MAB3270; Chemicon International
Inc., Temecula, Calif.) diluted 1:50 in BioGenex diluent containing 2% NSS and
1% BSA. At the end of the 72-h incubation, and after the slides were allowed to
warm to room temperature (30 min), they were rinsed with BPBS and then
subjected to 3% hydrogen peroxide (prepared in BPBS) treatment for 30 min.
The slides were rinsed thoroughly with BPBS and then preincubated for 30 s with
biotinylated rat anti-mouse IgM secondary antibody (catalog no. 553406 isotype
rat [LOU] IgG2a,; BD Pharmingen, San Diego, Calif.) diluted 1:200 in Bio-
Genex diluent. The reagent was then dumped off the slides with no intervening
buffer rinse and subjected to the same biotinylated secondary antibody reagent
for another 40 min. Subsequently, sections were incubated for 35 min with
super-sensitive streptavidin-conjugated peroxidase (BioGenex), rinsed thor-
oughly with BPBS, allowed to soak in BPBS for 5 min, and then subjected to a
5-min exposure to Nova Red chromogen. The sections were counterstained for
3 min in one-quarter-strength acidified hematoxylin, rinsed with ultrapure water
three times, and finished up through coverslipping following the same series of
procedures mentioned above (from this point on) for PI-3 IHC. Areas exhibiting
a reddish precipitate were accepted as positive IHC reactions. Control sections,
which instead of mouse IgM anti-SP-A primary antibody received either 1:50
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normal mouse IgG or 1:50 normal mouse serum (mouse IgM-containing serum;
Sigma) in BioGenex diluent (also containing 2% NSS and 1% BSA), lacked
staining. Lung tissues from all 18 animals were evaluated.
Scoring system. At least five fields from two hematoxylin and eosin lung
sections from each animal were examined by light microscopy (4/0.10 objective;
Olympus) and scored for lesion severity using a predetermined scale: briefly, for
lesion scores, 0, no inflammatory cells; 1, 1 to 30% of lung sections affected (mild
pneumonia); 2, 30 to 60% of lung sections affected (moderate pneumonia); 3,
60% of lung sections affected (severe pneumonia).
For IHC scoring, a minimum of five fields were assessed for viral-antigen
distribution and SP-A protein distribution and intensity within the lungs of
control and infected animals by using a light microscope (40/0.65 objective;
Olympus). Scoring was based on a predetermined scale: for PI-3 viral-antigen
staining, 0, no staining of cells; 1, 30% of bronchioles had detectable staining
in 5 cells (type II cells)/bronchiole in which macrophages stained; 2, 30% of
bronchioles had detectable staining in 10 cells (type II cells)/bronchiole in
which occasional macrophages stained; 3, 30% of bronchioles had detectable
staining in 10 cells (type II cells)/bronchiole in which rare macrophages
stained; for the distribution and intensity of SP-A protein staining, 0, no staining
of cells; 1, 30% of epithelial cells/bronchiole stained with minimal detectable
intracytoplasmic staining; 2, 30 to 60% of epithelial cells/bronchiole stained with
50% of the cell cytoplasm stained; 3, 60% of epithelial cells/bronchiole
stained with 50% of the cell cytoplasm stained. Mean values and standard
errors of the mean (SEM) were calculated for each group.
Fluorogenic real-time RT-PCR. For two-step fluorogenic real-time RT-PCR,
total RNA was isolated using TRIZOL (TRIZOL Reagent Ultrapure; Invitro-
gen) in our own optimized procedure (10), and DNase treatment of 18 separate
total RNA isolates was performed using Promega (Madison, Wis.) RQ1 RNase-
free DNase reagents and guidelines immediately prior to cDNA synthesis using
reagents (reverse-transcription reagents kit, 10 PCR buffer II, and 25 mM
MgCl2 solution) and guidelines from Applied Biosystems Inc. (ABI; Foster City,
Calif.). The total cDNAs, corresponding to each total-RNA sample isolate, were
then used as templates during fluorogenic real-time RT-PCR. Random hexamers
were used to prime each of our reverse-transcription reactions, and human 18S
rRNA was chosen as the housekeeping-reference gene.
Total-RNA isolation from lung by TRIZOL. In a nuclease-free 50-ml conical
centrifuge tube, 0.3 g of lung tissue (previously stored at80°C) from each of the
18 animals was combined with 3 ml of TRIZOL reagent and homogenized for
30 s using a 	H electric homogenizer (Omni International Inc., Gainesville, Va.).
The homogenate was allowed to sit for 5 min, after which 0.6 ml of chloroform
(nuclease free; Fisher Scientific) was added and the mixture was shaken vigor-
ously for 15 s. The sample was allowed to sit for 3 min at room temperature and
then was split into three nuclease-free 1.5-ml tubes and microcentrifuged at
15,600  g and 4°C for 10 min, after which the aqueous (top) layers were
transferred to a new nuclease-free 50-ml tube (recombining all partial sample
volumes). Isopropanol (nuclease free 2-propanol [1.5 ml]; Fisher Scientific) was
then added to the aqueous layer, and the solution was mixed and allowed to
stand for 10 min at room temperature. The mixture was then split into two
nuclease-free 1.5-ml vials and microcentrifuged for 10 min at 15,600 g and 4°C.
The isopropanol layer was poured off of each vial; large white RNA pellets were
visible at this point. Each pellet was washed three times with 0.5 to 1 ml of
precooled (20°C) 75% ethanol. The pellets were washed twice with 75% eth-
anol, followed by the third addition of 0.5 to 1 ml of 75% ethanol and vortexing
until the pellets were dislodged. The samples were then microcentrifuged for 5
min at 15,600  g and 4°C, and the ethanol was carefully poured off. The pellets
were allowed to air dry for 20 to 40 min at room temperature under a laminar
flow hood with the vial caps open. The dried pellets were resolubilized in a total
of 500 	l of RNA sample dilution buffer (Ambion nuclease-free water containing
0.1 mM EDTA). RNA sample pellets that were difficult to resolubilize were
warmed to 65°C in a heating block for 5 min and gently agitated in solution, and
then like samples were pooled in a single nuclease-free 1.5-ml vial. To assess the
quantity and purity of the RNA isolates, spectrophotometer (model DU 640B;
Beckman Instruments Inc., Fullerton, Calif.), readings of each total-RNA isolate
(diluted 1:40 with RNA sample dilution buffer) were taken at 260 and 280 nm.
The spectrophotometer was zeroed with RNA sample dilution buffer. Absor-
bances at 260 nm indicating RNA concentrations of 0.2 	g/	l were required in
order for each RNA sample to be concentrated enough for the fluorogenic
real-time RT-PCR procedure to proceed successfully. All RNA sample A260/A280
ratios fell between 1.75 and 1.9, indicating very pure RNA in all cases. All
total-RNA samples were stored at 80°C for no longer than 30 days prior to
being used as templates for total-cDNA synthesis by reverse transcription.
DNase treatment of RNA isolates and cDNA synthesis by reverse transcrip-
tion. Prior to cDNA syntheses, each total-RNA isolate was subjected to DNase
treatment using a commercially available kit (RQ1 RNase-free DNase reagents;
Promega) and a thermocycler (GeneAmp PCR System 2400; Perkin-Elmer LLC,
Norwalk, Conn.). DNase treatments of total-RNA isolates were performed in
200-	l MicroAmp optical tubes (ABI) using GeneAmp 2400 thermocycling con-
ditions of 30 min at 37°C, followed immediately by manually pausing the program
in order to add RQ1 DNase stop solution (Promega); 1 	l of stop solution per
	g of RNA present in each DNase reaction mixture was added to each tube,
after which the mixture was gently vortexed and then quickly returned to the
2400 thermocycler to resume and finish the program with a 10-min hold at 65°C
and a final safety hold at 4°C. Directly after DNase treatments, cDNAs were
made from each of the RQ1 DNase-treated, TRIZOL-isolated total-RNA sam-
ples using the ABI reagents mentioned above for reverse transcription as follows:
2 	g of DNase-treated RNA was added to each 100-	l reverse-transcription
reaction mixture volume, which was assembled to contain final concentrations of
1 TaqMan PCR buffer II, 5.5 mM MgCl2, 2 mM deoxyribonucleoside triphos-
phate mixture (500 	M each deoxyribonucleoside triphosphate present), 2.5 	M
random hexamers, 1.25 U of murine leukemia virus (also known as Multiscribe)
RT/	l, and 0.4 to 0.8 U of RNase inhibitor (ABI)/	l. The reverse-transcription
reaction thermocycling conditions were 10 min at 25°C, 30 min at 48°C, and 5
min at 95°C. A portion of each of the resulting cDNA samples was immediately
diluted 1:5 with nuclease-free water and stored at 20°C. In addition, positive
(TaqMan rRNA control reagents; ABI) and negative (nuclease-free water) RNA
controls were prepared and subjected to the same procedures as each of the
total-RNA sample isolates (the positive control human RNA was diluted to 0.001
	g/100 	l of reverse-transcription reaction volume, as suggested by the accom-
panying ABI product literature).
Primer and probe design. Sequence-specific oligonucleotide primers and flu-
orescent probe for detection and relative quantification of cDNA corresponding
to each target mRNA of interest (ovine SP-A and SP-D and SBD-1) were
designed using ABI Prism Primer Express version 2.0 software and were selected
to be within the coding sequence of each mRNA. Final selected primer and
probe sequences were additionally screened by comparing them for similarity to
all available DNA and mRNA sequences via the Basic Local Alignment Search
Tool (National Center for Biotechnology Information), and only unique se-
quences were used for primer and probe design. Ovine SP-A nucleic acid se-
quences included forward primer (5
-TGACCCTTATGCTCCTCTGGAT-3
),
reverse primer (5
-GGGCTTCCAAGACAAACTTCCT-3
), and probe (5
-
6FAM-TGGCTTCTGGCCTCGAGTGCG-TAMRA-3
). Ovine SP-D nucleic
acid sequences included forward primer (5
-ACGTTCTGCAGCTGAGAAT-
3
), reverse primer (5
-TCGGTCATGCTCAGGAAAGC-3
), and probe (5
-6F
AM-TTGACTCAGCTGGCCACAGCCCAGAACA-TAMRA-3
). SBD-1 nu-
cleic acid sequences included forward primer (5
-CCATAGGAATAAAGGCG
TCTGTGT-3
), reverse primer (5
-CGCGACAGGTGCCAATCT-3
), and probe
(5
-6FAM-CCGAGCAGGTGCCCTAGACACATGA-TAMRA-3
). (6FAM is
6-carboxyfluorescein, the fluorescent reporter dye, and TAMRA is 6-carboxytetra-
methylrhodamine, the fluorescent quencher dye.) The sequence-specific oligonucle-
otide primer-probe set we used to detect the cDNA that corresponded to our chosen
endogenous reference (housekeeping) gene, 18S rRNA (to which we normalized all
detected real-time signals for ovine SP-A and SP-D and SBD-1), was purchased
commercially (TaqMan rRNA Control Reagents; ABI).
Optimization and validation tests. The GeneAmp 5700 sequence detection
system allowed dual amplification and analysis of cDNAs corresponding to both
a target gene of interest and the endogenous reference gene concurrently on the
same plate but within separate wells. Optimization and validation experiments
were performed as suggested by ABI in order to find the correct concentrations
of primers and probes to use for each target, as well as the optimal useful dilution
of cDNA (found to be 1:5 in previous studies) that would allow each PCR to
proceed with optimum efficiency. To accomplish this, two separate optimization
plates were set up for each target, one to optimize the primer concentration and
another to optimize the probe concentration. For all optimization trials, each
sample was analyzed in quadruplicate. The first plate was designed to enable the
testing of various combinations and concentrations of the forward and reverse
primers, ranging from 50 to 900 nM, while the probe amount remained fixed. In
each well, the 50-	l PCR mixtures contained a constant concentration of target
probe (200 nM), 5 	l of 1:5-diluted target-inclusive Stock I cDNA, 25 	l of a
commercial master mix (TaqMan Universal PCR Master Mix 2X; ABI), and
nuclease-free water (used to adjust each final volume to 50 	l). (Stock I cDNA
is predetermined cDNA from Ewe [no. 265] that was shown by a preliminary,
nonoptimized real-time test plate to express positively for SP-A, SP-D, and
SBD-1. The 1:5 dilution refers to the dilution of full-strength Stock I cDNA [or
any other sample cDNA whose original concentration is that which is obtained
directly from each reverse-transcription reaction, which is theoretically 0.02 	g of
VOL. 11, 2004 EFFECT OF PI-3 VIRUS ON INNATE IMMUNITY 601
 o
n
 February 25, 2013 by IO
W
A STATE UNIVERSITY
http://cvi.asm
.org/
D
ow
nloaded from
 
cDNA/	l, assuming 100% efficiency of each reverse transcription].) All plates
were run in the GeneAmp 5700 sequence detection system real-time PCR ma-
chine (ABI) using the following thermocycler conditions: hold for 2 min at 50°C,
hold for 10 min at 95°C, and 50 cycles of 15 s at 95°C, followed by 1 min at 60°C.
Each 50-cycle run lasted 2 h and 22 min, after which the GeneAmp 5700
sequence detection system software and Microsoft Excel were used in conjunc-
tion to analyze the resultant fluorogenic PCR amplification data. For the first
optimization plate for each target, primer amounts that, upon analysis, provided
the highest Rn (normalized reporter) value with the lowest primer concentra-
tion(s) were identified as the optimal concentrations for each primer pair for
each of the respective targets of interest. (Rn  Rn  Rn, where Rn is the
Rn value of a reaction containing all components and Rn is the Rn value of an
unreacted sample [the baseline value or the value detected in the no-template
control].) A second plate was designed for each target to enable the testing of
various concentrations of each probe, ranging from 25 to 225 nM, in the presence
of optimal primer concentrations (as established by plate 1 in each case). In each
well, the 50-	l PCR mixture contained the identified optimal concentrations of
the primer (which we found to be 300 and 300 nM for ovine SP-A, 300 and 300
nM for ovine SP-D, and 300 and 900 nM for SBD-1 forward and reverse primer
concentrations), 5 	l of 1:5-diluted Stock I cDNA, 25 	l of the ABI commercial
master mix (see above), and nuclease-free water. For the second plate for each
target, upon analysis of the resultant data, the combination of reactants which
yielded the lowest threshold cycle (CT) (the cycle at which a significant increase
in Rn is first detected) with the lowest probe concentration was chosen as the
optimal fluorogenic-probe concentration in each case (we found these to be 50,
100, and 150 nM for ovine SP-A, SP-D, and SBD-1 probes, respectively). Next,
as a validation test that the target and endogenous reference cDNA amplification
reactions were all proceeding at equal efficiencies across a spectrum of Stock I
cDNA concentrations, a third plate (the validation test plate) was designed to
test various concentrations of cDNA ranging from full-strength Stock I cDNA to
a 1:15,625 dilution of Stock I cDNA. In each well, constant (optimal) concen-
trations of forward and reverse primers and constant (optimal) concentrations of
probes were used, along with 25 	l of the ABI master mix, 5 	l of sequentially
diluted Stock I cDNA, and nuclease-free water. Also included on this plate were
wells identical to the ones described above, but instead of ovine target primers
and probe they contained the endogenous reference (human 18S rRNA) forward
and reverse primers and probe at their ABI-established optimal real-time con-
centrations. This plate included all samples in triplicate and was run in the
GeneAmp 5700 sequence detection system with conditions identical to those
used in the optimization tests. Upon analysis of the resultant data for each cDNA
concentration, the CT of the endogenous reference was subtracted from the CT
of the target, and this value (CT) was plotted against the log concentration of
input cDNA. A resultant line with a slope of 0.1 was considered to represent
cDNA amplification reactions of target and endogenous references with equal
efficiencies across the various cDNA concentrations tested. As the slope was not
0.1 in any case (for SP-A, SP-D, and SBD-1), the standard-curve method was
used for data analysis of all three real-time PCR amplification reactions (if the
slope had been 0.1, the CT method for data analysis would have been used).
PCR. Separate microwell plates were designed to carry out fluorogenic real-
time RT-PCR using the cDNA prepared previously from all 18 sheep samples,
with three replicates run for each sample and three replicates of a negative
control (nuclease-free water) on each plate. In addition, on each plate were three
replicates each of five serial progressive 1:5 dilutions of the Stock I cDNA that
served in the generation of a standard curve for both the target and the refer-
ence, as well as three replicates containing cDNA from the calibrator sheep lung
(to which all samples could be compared but which we chose not to use in the
present study). On each plate, both target and endogenous reference wells were
run simultaneously for all samples represented on that plate. Each assay com-
position was as follows: in each well, the 50-	l PCR mixtures contained 25 	l of
the commercially available ABI master mix, 5 	l of a 1:5 dilution of the cDNA
to be tested (or nuclease-free water for the negative no-template control), the
established optimal forward and reverse primers and probe concentrations in
each case for the signal of interest in that well, and nuclease-free water. All such
plates were run in the GeneAmp 5700 sequence detection system under condi-
tions identical to those used with the optimization and validation test plates
described above.
Using the GeneAmp 5700 software in conjunction with a departmentally
designed Excel file, all resultant data were analyzed as follows. Each target signal
was normalized to its corresponding reference signal (18S rRNA) by dividing the
target input amount of cDNA by the reference input amount of cDNA for each
replicate, followed by calculation of the average and standard deviation of all
replicates from each sheep. At this point, the normalized target values from each
animal could have been expressed relative to the calibrator animal’s signal for
each particular target (where the chosen calibrator cDNA target of interest
would have been assigned a value of 1), but we decided against using the
calibrator (control saline-treated lamb no. 8; the lowest SBD-1 expresser), since
other real-time studies have demonstrated high interanimal variability of lung
SBD-1 levels among control sheep (J. M. Caverly and M. R. Ackermann, un-
published data).
Quantitative-competitive ELISA for SP-A protein. A previously described
quantitative-competitive enzyme-linked immunosorbent assay (ELISA) proce-
dure (38) was used to assess lung samples for the presence of the SP-A protein.
The procedure was performed in 96-well microtiter plates (Immulon I; 12.8- by
8.6-cm 96-well flat-bottom polystyrene plates; Dynatech Laboratories Inc., Chan-
tilly, Va.). Briefly, 0.2 g of lung tissue and 0.8 ml of PBS (10 mM Na2HPO4, 1.8
mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4) were combined and homog-
enized with a TH tissue homogenizer (OMNI International Inc., Warrenton,
Va.) for 30 s on ice. Samples were then sonicated on ice three times at 10-s
intervals at 40% amplitude with a sonicator (model 550 Sonic Dismembrator,
using the two-part microtip setup; Fisher Scientific). The resulting lung solutions
were then clarified by microcentrifugation at 4°C for 5 min at 15,600  g
(Eppendorf model 5414; fixed speed), after which the supernatants were stored
at 20°C. The lung homogenate supernatants were diluted 1:1,000 with high-
performance liquid chromatography (HPLC)-grade water (Fisher Scientific) just
before the assay. A standard curve was prepared using purified SP-A peptide
and/or standard sheep bronchoalveolar lavage (BAL) fluid (courtesy of Jeffrey
Whitsett) (38), which allowed the comparison of lung samples to known amounts
of either SP-A peptide (0.05 to 10 ng/ml or mg) or equivalent amounts of BAL
fluid (which we found to be in the 1:6  106 to 1:2.5  105 dilution range of
standard sheep lung BAL fluid). Serially diluted 2 SP-A peptide standard
solutions were prepared in the range of 0.1 to 20 ng/ml from a 5,400-ng/ml stock
solution of purified SP-A. All standards and samples were administered in
triplicate to wells of a standard 96-well microtitration plate. The wells were
coated overnight with a 1:200 dilution of standard sheep BAL fluid in bicarbon-
ate coating buffer (0.42 g of NaHCO3 in 50 ml of HPLC-grade water). During the
same period, 300 	l of the 2 SP-A peptide standard solutions, equivalent
standard sheep BAL fluid dilutions, and appropriately diluted sample unknowns
were added to 300 	l of a 2 primary antibody solution made by combining 2 	l
of a 50% rabbit (R436) anti-SP-A IgG antibody (courtesy of Jeffrey Whitsett)
with 1 ml of 100% normal goat serum (Sigma), 4.998 ml of HPLC-grade water,
and 4 ml of a 5 diluent (50 mM Tris-HCl; 750 mM NaCl; 2.5% IgG-free,
protease-free BSA [Jackson Immunoresearch Laboratories]; pH 7.4) and incu-
bated overnight at 37°C. The next day, the wells and plates were washed three
times with a wash buffer (5 mM Tris-HCl, 0.05% Tween 20 [catalog no. P-9416;
Sigma] at pH 8.0), the plate was tapped thoroughly of excess fluid into a Terri
cloth, and 200 	l of 5% normal goat serum in diluent (10 mM Tris-HCl; 150 mM
NaCl; 0.5% IgG-free, protease-free BSA; pH 7.4) was added to each well and
allowed to incubate for 15 min at room temperature. This solution was subse-
quently shaken from the wells, and the plate was blotted dry. Next, 100 	l of each
of the SP-A standard-antibody, sheep BAL fluid standard-antibody, and sample-
antibody overnight-incubated mixtures was added to appropriate wells to allow
unbound primary antibody in each solution to bind (BAL–SP-A) antigen. Blank
wells received unchallenged 1:20,000-diluted primary antibody (initially diluted
1:10,000; used at a final concentration of 1:20,000 in each well) solution at this
time. The plate was allowed to incubate for 1 to 2 h at 37°C, the fluid was shaken
from the wells, and the plate was washed three times. Immediately after this, 100
	l of a 1:1,000 dilution of a goat anti-rabbit-horseradish peroxidase conjugate
(catalog no. 474-1506; goat anti-rabbit horseradish peroxidase IgG; Kirkegaard
& Perry Laboratories) in PBS-Tween buffer (50 mM anhydrous Na2HPO4, 50
mM NaH2PO4  H2O, 150 mM NaCl, and 0.05% Tween 20, pH 7.4) containing
5% NSS was added to each well and allowed to incubate for 1 h at 37°C. The fluid
was again shaken from the wells, rinsed three times with wash buffer, and washed
once with PBS, pH 7.4 (PBS without Tween 20), followed by the addition of 100
	l of ABTS [2,2
-azinobis(3-ethylbenzthiazolinesulfonic acid)] peroxidase sub-
strate solution (Kirkegaard & Perry Laboratories) to each well. The substrate
reaction was allowed to proceed for 12 min at room temperature and was
stopped by the addition of 100 	l of 0.75% sodium dodecyl sulfate solution
(made from 10% lauryl sulfate solution; Sigma) to each well. The different color
intensities in the wells were measured in an MR700 microplate reader (Dynatech
Laboratories Inc.) at 410 nm. Finally, percent inhibition (calculated as a function
of average sample absorbances divided by the average blank-well absorbance)
versus concentration of SP-A standards (and/or equivalent dilutions of standard
sheep BAL fluid) was plotted, and the resultant standard curve was used to
estimate unknown SP-A concentrations in lung samples. All dilution factors
incurred by samples throughout the course of the procedure were taken into
account so that the final numbers of nanograms of SP-A per milligram of sheep
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lung tissue were reflective of the actual lung SP-A levels in each lamb. Nasal
septa, trachea, and other upper respiratory tissues were not evaluated for sur-
factant proteins in this study; only lung tissues from all 18 animals were assessed.
Statistical analysis. Nonparametric Kendall’s tau-b correlation tests (42) were
used to determine if there was any correlation among histopathological values,
IHC values, and time effect within each group. Kendall’s tau-b statistics were
tested against zero. Nonparametric Wilcoxon tests (42) were used to determine
if there was any statistically significant difference between histopathological le-
sions or IHC values in the two groups. Values were considered to be significant
when P was 0.05. For fluorogenic real-time RT-PCR, statistical analysis was
performed using the means of SBD-1, SP-A, or SP-D mRNA levels from three
replicate wells per sheep normalized to the reference. To determine if there were
significant treatment and time effects, a t test assuming unequal variances was
used (42). Values were considered to be significant when P was 0.1. For
quantitative-competitive ELISA, the means of SP-A protein levels from three
replicate wells per sheep were assessed. The final numbers of nanograms of SP-A
per milligram of sheep lung tissue for all sheep were analyzed by using a t test
assuming unequal variances in order to determine if there were significant
treatment and time effects. Values were considered to be significant when P was
0.05. The software used was JMP release 5.0 (SAS Institute Inc. Cary, N.C.).
RESULTS
Clinical signs. Lambs inoculated with the PI-3 virus, but not
control lambs, developed clinical signs of respiratory infection
as previously described (15, 36). Briefly, the infected animals
were reluctant to move, had reduced activity and expiratory
dyspnea (“thumping”), showed intermittent coughing, had re-
duced feed intake, and developed a sustained, mild increase in
body temperature ranging from 102.6 to 106.6°F during the
first 7 days p.i. The febrile response appeared to be biphasic,
and it peaked on days 1 (average temperature, 104.6  0.28°F)
and 5 (average temperature, 104.9  0.40°F) p.i. in PI-3 virus-
infected lambs.
Serology. Postinoculation serum antibody titers to PI-3 virus
varied from 1:8 to 1:64 among animals but were not signifi-
cantly increased in infected lambs compared to preinoculation
values and control animals.
Gross pathology. The predominant gross lesions included
extensive multifocal consolidation in all infected lobes with
slight predominance of ventral to cranioventral distribution
involving 20 to 90% of the lobes. Frequently, there was also
mild interlobular edema and multifocal hyperinflation of the
lobules. The control animals lacked lesions.
Histopathology. The lesions were similar to those reported
previously in slightly older (7-day-old) lambs (15). On day
3 p.i., lesions were characterized by mild to moderate multifo-
cal necrotizing acute bronchiolitis and bronchointerstitial
pneumonia. On day 6 p.i., there was histiocytic and suppurative
interstitial pneumonia accompanied by type II pneumocyte
hypertrophy and hyperplasia, and bronchiolitis with epithelial
cell hyperplasia. On day 17 p.i., there was mild fibrous inter-
stitial pneumonia with lymphohistiocytic peribronchitis, peri-
bronchiolitis, and perivasculitis in the PI-3 virus-infected
group. The control animals lacked lesions.
IHC for PI-3 viral antigen. PI-3 viral antigen was present in
all three PI-3 virus-infected lambs at 3 days p.i. and was de-
tected in 30% of bronchioles with microscopic lesions in
these lambs. PI-3 viral antigen was present within the cyto-
plasm of the bronchiolar epithelial cells and only in rare mac-
rophages and type II pneumocytes and also very rarely in the
bronchial epithelial cells (Fig. 1A). On day 6 p.i., PI-3 viral
antigen was present in two-thirds of infected animals and in
macrophages and type II pneumocytes and was only rarely
present in bronchiolar epithelial cells (Fig. 1C). PI-3 viral an-
tigen was absent on day 17 p.i. (Fig. 1E). The control animals
lacked PI-3 viral antigen (Fig. 1B, D, and F).
There was a high correlation between the day p.i. and the
IHC values for PI-3 viral antigen. That is, the IHC values for
PI-3 viral antigen decreased with time. The correlation was
0.87 for the PI-3 virus-infected group (P  0.0048). There
was no statistically significant difference between the severity
of histopathological lesions and IHC values for PI-3 viral an-
tigen (P  0.4498 for histopathological lesions; P  0.8965 for
IHC values) (Table 1).
Expression of SBD-1. SBD-1 in the lung was assessed by
fluorogenic real-time RT-PCR of cDNA prepared from ho-
mogenized lung. When normalized to 18S rRNA levels, there
was a trend of increased SBD-1 mRNA expression on all days
p.i. (3, 6, and 17 days) compared to the control animals. The
increase was statistically significant on day 17 p.i. (Fig. 2).
Expression of SP-A. SP-A was assessed by fluorogenic real-
time RT-PCR, quantitative-competitive ELISA procedures on
lung homogenates, and IHC on lung sections. SP-A mRNA
levels increased significantly 6 and 17 days following PI-3 virus
infection compared to levels in the control animals (Fig. 3).
SP-A protein levels in lung homogenates assessed by quanti-
tative-competitive ELISA were not significantly altered by PI-3
virus infection (Fig. 4). The intensity of staining for SP-A
protein assessed by IHC (Table 2) agreed with quantitative-
competitive ELISA results for SP-A protein in lung homoge-
nates. The IHC staining distributions for SP-A in both control
and infected animals were predominantly present within the
cytoplasm of nonciliated bronchiolar cells (most intense in the
apical portion) and less often in type II pneumocytes and
macrophages. In the infected animals on day 3 p.i., there was
a mild decrease in staining distribution and intensity which was
most obvious within the consolidated areas, where there was a
loss (necrosis) of bronchiolar epithelial cells.
Expression of SP-D. SP-D in the lung was assessed by flu-
orogenic real-time RT-PCR. SP-D mRNA levels were signifi-
cantly increased in the lung during PI-3 virus infection on all
days p.i. compared to those in the control animals (Fig. 5).
DISCUSSION
SBD-1 (like HBD-1), SP-A, and SP-D, are constitutively
expressed in the normal lung (12, 13, 29). Constitutive expres-
sion of SBD-1, SP-A, and SP-D allows a constant presence of
these factors in airways to defend against infection and to help
prevent the initial attachment of microbes to the respiratory
mucosa. Despite reported constitutive expression, our results
suggest that PI-3 virus infection enhances levels of SBD-1,
SP-A, and SP-D mRNAs. The mechanism by which PI-3 virus
enhances expression was not determined; however, SP-A and
SP-D expression can be increased in response to a variety of
stimuli, including glucocorticoids (18) and vascular endothelial
cell growth factor (9). In contrast, tumor necrosis factor alpha
reduces SP-A expression (49). It could also be that PI-3 virus
infection enhances the expression of constitutive genes globally
in proliferative type II cells that replace virus-infected cells,
or PI-3 virus infection may enhance the stability of certain
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FIG. 1. IHC detection of PI-3 viral antigen in the lungs of lambs inoculated with PI-3 virus or sterile medium 3 (A and B), 6 (C and D), or 17
(E and F) days p.i. (A) PI-3 viral antigen is present within the cytoplasm of bronchiolar epithelial cells. (C) PI-3 viral antigen is present within the
cytoplasm of macrophages and bronchiolar epithelial cells. (E) Bronchioles in lungs from lambs 17 days p.i. lack PI-3 viral antigen. (B, D, and F)
Control animals lack PI-3 viral antigen. Bar  100 	m.
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mRNAs, including those of SBD-1, SP-A, and SP-D, in in-
fected or proliferative cells.
The increase in SBD-1, SP-A, and SP-D mRNA levels and
the simultaneous decrease in PI-3 virus replication may suggest
that these factors are synthesized in order to bind to PI-3 virus,
as collectins bind to other viruses, and to neutralize it directly
or indirectly. Indirect activity may be accomplished via several
mechanisms. First, SP-A and SP-D can trigger macrophage
activity (40), causing the clearance of RSV (39) and influenza
virus (12, 43). Secondly, studies demonstrate that beta-de-
fensins may cause chemotaxis of dendritic cells and lympho-
cytes to the site of infection in order to promote adaptive
immunity (50). Furthermore, there is strong evidence that
Toll-like receptor 4 is involved in the innate response to other
paramyxoviruses (RSV) (26) and that it can be activated by
murine beta-defensin 2 (5). In addition, SBD-1, SP-A, and
SP-D may also affect interferon activity in order to enhance
antiviral activity (11). The mechanism of direct antiviral activ-
ity by SBD-1 may be through its ability to induce pore forma-
tion in the PI-3 viral envelope; however, this remains to be
determined. Recently, alpha-defensins have been shown to
induce anti-HIV-1 activity (52). Although increased expression
of the mRNAs of these innate immune factors and decreased
viral replication may be unrelated phenomena, our present
data suggest that this response of the respiratory tract is likely
virus specific. Bacterial (Mannheimia haemolytica) infection,
when introduced in particularly high concentrations, signifi-
cantly reduced SBD-1 mRNA expression in the sheep lung
compared to that in uninfected controls (M. R. Ackermann
and J. M. Gallup, unpublished data).
Our present observation of increased lung SP-A mRNA
levels in the absence of significant changes in SP-A protein
expression in lung homogenates and histological sections may
be due to several reasons. We suspect that there may be in-
creased production of SP-A mRNA (and perhaps protein), but
this increase could also be accompanied by lymphatic drainage
or direct uptake of SP-A protein by the pulmonary capillaries
due to damage to the epithelium-endothelium barrier (25).
Alternatively, utilization of the SP-A protein may be increased
due to its binding and aggregation of PI-3 virions. Both possi-
bilities support steady levels of SP-A protein in the lung, which
has previously been shown in the BAL fluid of children in-
FIG. 2. SBD-1 mRNA levels detected in whole-lung homogenates
of PI-3 virus-inoculated and control lambs by fluorogenic real-time
RT-PCR. There was a trend toward increased SBD-1 mRNA levels in
the PI-3 virus-infected group on days 3 and 6 and a significant increase
(*) on day 17 compared to the control animals (P  0.06). A t test
assuming unequal variances was used. The error bars indicate SEM.
FIG. 3. SP-A mRNA levels detected in whole-lung homogenates of
PI-3 virus-inoculated and control lambs by fluorogenic real-time RT-
PCR. SP-A mRNA levels were significantly increased (*) in PI-3 virus-
inoculated lambs 6 and 17 days p.i. compared to the control animals (P
 0.09 for day 6 p.i. and P  0.05 for day 17 p.i.). A t test assuming
unequal variances was used. The error bars indicate SEM.
FIG. 4. SP-A protein levels assessed by quantitative-competitive
ELISA in whole-lung homogenates of PI-3 virus-inoculated and con-
trol lambs. SP-A protein levels were not significantly changed by PI-3
virus inoculation compared to the control animals. A t test assuming
unequal variances was used. The error bars indicate SEM.
TABLE 1. Lesion and IHC scores of PI-3 virus-infected and
control neonatal lambs 3, 6, and 17 days p.i.a
Day
p.i.
Control PI-3 inoculated
Lesion
scoreb
IHC
scorec Lesion score IHC score
3 0 0 2.00  0d 2.67  0.33d,e
6 0 0 2.67  0.33d 0.67  0.33e
17 0 0 1.00  0d 0
a PI-3 virus-infected lambs had lesions and viral antigen that were not present
in controls.
b Values are means for lesion score  SEM (three samples per group).
c Values are means for PI-3 viral-antigen IHC score  SEM (three samples
per group).
d Significantly increased compared to controls.
e Significantly increased compared to day 17 p.i.
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fected with RSV (31). Although another study of RSV-infected
children detected modest reduction of SP-A protein in the
BAL fluid of infected patients, the SP-A protein was found to
increase between the first and last day of sampling (31). Our
IHC assessment of SP-A relied solely on mouse IgM anti-SP-A
primary antibody, since all other commercial antibodies we
tested (all of which were IgG) did not work in this application.
In our study, protein expression was determined only for SP-A.
We are in the process of developing reagents and techniques
necessary to detect the expression of SP-D and SBD-1 proteins
as well.
There are few spontaneous models of PI-3 virus respiratory
tract infection, and we think that an ovine model may be a
good additional candidate. The ovine model used in this study
represents one of the few spontaneous models of PI-3 virus
respiratory tract infections, and sheep are commonly used for
the study of paramyxoviral pathogenesis and immunity (1, 4,
41). Ovine PI-3 virus is a member of the family Paramyxoviri-
dae and is similar to human PI-3 virus in antigenic epitopes,
epidemiology, and disease pathogenesis (15, 16, 36). PI-3 virus
infection results in consistent lesions, and the pathogenesis and
lesions (bronchiolar epithelial cell necrosis, inflammatory cell
infiltrate, and epithelial cell proliferation) in sheep are similar
to PI-3 virus infection in humans (7, 15, 23). Furthermore,
human neonates have elevated risk for severe PI-3 virus infec-
tion (23), and similarly, neonatal sheep infected with PI-3 virus
exhibit more severe lesions than older sheep (15, 36; B. Grubor
and M. R. Ackermann, unpublished data). In addition, innate
immunity in lambs can be readily studied without the influence
of maternal antibody, since placental passage of maternal im-
munoglobulins does not occur in ruminants, including sheep.
In this study, lambs were fed colostrum-containing milk in
order for them to experience a more natural neonatal phase of
life. The maternal antibodies may in some way influence each
lamb’s innate immune response; however, preinoculation se-
rum antibody titers to PI-3 virus were found to be low in all
animals. In addition, we found that the p.i. serum antibody
titers to PI-3 virus were not significantly increased in infected
versus control lambs, which was expected, since the p.i. time
was not long enough to generate a significant response in naïve
neonates. The consistency of our results, including clinical
signs and gross and histopathological lesions, indicates that
PI-3 virus in neonatal lambs reliably causes pneumonia and
consistently incites bronchiolar and alveolar lesions, as seen
previously in older lambs (7 days of age) with the same PI-3
virus strain (15, 36). In sheep, the normal body temperature is
102°F, while critical temperature is considered to be 104°F,
above which hyperthermia (fever) is said to be present (6). The
mild but long-lasting increases in the rectal temperatures of
the lambs infected with PI-3 virus in this study could be attrib-
uted to higher susceptibility of neonatal animals to the virus in
light of previous reports that older lambs do not have such
prolonged increases in temperature (36).
The IHC procedure we developed for the detection of PI-3
viral antigen more precisely defined viral-antigen distribution
than a previous immunofluorescence technique (2, 15). The
persistence and distribution of the PI-3 viral antigen as as-
sessed by IHC correlated well with the time effect. On day
3 p.i., viral antigen was widely distributed in 30% of the
damaged bronchioles, affecting smaller airways in particular.
Only rare macrophages and type II pneumocytes contained
antigen. On day 6 p.i., the virus persisted only in some animals
(two-thirds of the PI-3 group) and was present in macrophages
and type II pneumocytes, while hyperplastic repaired bronchi-
oles generally lacked the antigen. Complete clearance of virus
by day 17 p.i. corresponded with the resolution of lung lesions.
This work has determined the extent to which an important
paramyxoviral pathogen, PI-3 virus, alters the expression of
three important lung innate immune factors in neonatal lambs.
In future studies, we will use laser capture microdissection to
retrieve epithelium in order to localize SBD-1, SP-A, and SP-D
mRNA expression within various regions of lung epithelia
(bronchi, bronchioles, and alveoli) and to determine the alter-
ations that occur in these regions in PI-3 virus-infected ani-
mals. Early results obtained with laser capture microdissection
one-step fluorogenic RT-PCR (22) indicate that the highest
level of SBD-1 mRNA expression is present within the bron-
chial epithelial cells (Ackermann and Gallup, unpublished),
which generally lack PI-3 viral antigen and lesions during viral
pneumonia.
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FIG. 5. SP-D mRNA levels detected in whole-lung homogenates of
PI-3 virus-inoculated and control lambs by fluorogenic real-time RT-
PCR. SP-D mRNA levels were significantly increased (*) in PI-3 virus-
inoculated lambs 3, 6, and 17 days p.i. compared to the control animals
(P  0.09 for day 3 p.i., P  0.09 for day 6 p.i., and P  0.06 for day
17 p.i.). A t test assuming unequal variances was used. The error bars
indicate SEM.
TABLE 2. IHC scores for SP-A protein expression (distribution
and intensity) in the lungs of PI-3 virus-infected and control
neonatal lambs 3, 6, and 17 days p.i.a
Day p.i.
Control PI-3 inoculated
Distribution Intensity Distribution Intensity
3 3  0 3  0 1.5  0.41 2  0
6 2.33  0.33 2.33  0.33 2  0.58 2  0
17 3  0 2.33  0.33 2  0.58 2.33  0.33
a SP-A protein distribution was not significantly altered by PI-3 virus infection.
Values are means for SP-A IHC score  SEM (three samples per group).
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